Dr Mandana Nikpoud, St Vincent’s Hospital, Melbourne
The SPHInX Study is testing a new treatment for Scleroderma-related Pulmonary Arterial Hypertension. The purpose of the SPHInX Study is to determine whether there are any health benefits to be gained from the addition of a blood-thinning medication, Apixaban, for patients with Scleroderma-related Pulmonary Arterial Hypertension in addition to their already prescribed therapy.
You may be eligible to participate if;
The following study procedures will be performed during most visits:
You will also receive regular telephone calls from the study team, to confirm your current medications and to ask questions about any changes to your health. You will also be asked to complete a health diary. Most visits are timed to occur at the same time as your normal, 6 monthly, clinic visits, limiting the number of additional visits you need to attend to participate in the study.
31 December, 2017
This study has been approved by St Vincent’s Hospital, Melbourne (project number HREC/14/SVHM/15). This research is funded by a National Health and Medical Research Council (NHMRC) Project Grant.
To express your interest in participating in this study please contact:
Ms Kate Scott
Clinical Trial Coordinator, St Vincent’s Hospital, Melbourne
Telephone: 03 9231 3981